Hepatotoxicity of antituberculosis chemotherapy in patients with liver cirrhosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Immunoallergic manifestations of antituberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004
Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Antituberculosis drug- induced hepatitis, an unpredictable phenotype Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Antioxidants and extracorporal detoxication in therapy of idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Antituberculosis chemotherapy toxicity reduction Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
Effect of pulse therapy with glucocorticoid and cyclophosphamide on lung fibrosis due to paraquat poisoning in rat Source: Annual Congress 2010 - New insights into reactive oxygen species Year: 2010
The renal oxidative stress induced by tuberculostatic treatment correlated with nephrotoxic markers Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
The oxidative stress determination on patients trated with tuberculostatic drugs Source: Eur Respir J 2003; 22: Suppl. 45, 154s Year: 2003
Thymalin as an immunomodulation option in severe COVID-19 Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021
Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001
Side-effects of antituberculosis drug treatment in patients with chronic renal failure Source: Eur Respir J 2002; 20: 440-443 Year: 2002
Effectiveness of treatment and correction of side effects in pulmonary MDR/XDR TB patients with concomitant liver injury Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Antioxidants and anticytokines in the prevention of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 108s Year: 2004
Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002